A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT04524403
- Locations
- ๐บ๐ธ
Site # 240, Chicago, Illinois, United States
๐บ๐ธSite #166, Philadelphia, Pennsylvania, United States
๐บ๐ธSite #143, Bentonville, Arkansas, United States
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT04373265
- Locations
- ๐บ๐ธ
Site #183, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธSite #030 Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธSite #150, Stanford Cancer Center, Stanford, California, United States
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT04329949
- Locations
- ๐บ๐ธ
Site #186, Toledo, Ohio, United States
๐บ๐ธSite #009, Atlanta, Georgia, United States
๐บ๐ธSite #058, Detroit, Michigan, United States
Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 137
- Registration Number
- NCT04308590
- Locations
- ๐บ๐ธ
Site 21, Columbus, Ohio, United States
๐บ๐ธSite 27, Birmingham, Alabama, United States
๐บ๐ธSite 17, Stanford, California, United States
Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 110
- Registration Number
- NCT04249323
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT03877952
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03878264
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, Nottingham, United Kingdom
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT03877562
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03823703
- Locations
- ๐บ๐ธ
Site 208, Glendale, Arizona, United States
๐บ๐ธSite 234, Port Orange, Florida, United States
๐บ๐ธSite 215, Edinburg, Texas, United States
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT03818256
- Locations
- ๐บ๐ธ
Site 239, Garden Grove, California, United States
๐บ๐ธSite 143, Bentonville, Arkansas, United States
๐บ๐ธSite 249, Little Rock, Arkansas, United States